A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status
Sandro Pignata,Amit M. Oza,Geoff Hall,Beatriz Pardo,Radoslaw Madry,David Cibula,Jaroslav Klat,Ana Montes,Rosalind Glasspool,Nicoletta Colombo,Imre Pete,Ana Herrero,Margarita Romeo Marin,Rumyana Ilieva,Constanta Timcheva,C. Blakeley,Rosie Taylor,Alan Barnicle,Andrew R Clamp +18 more
TL;DR: PFS in patients with platinum-sensitive relapsed ovarian cancer who received maintenance olaparib was similar irrespective of s or g BRCAm status, as well as HRQoL and tolerability, which were consistent with previous olAParib studies in this population.
Journal ArticleDOI
Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa
Laudine Communal,Mauricio Medrano,Mauricio Medrano,Fabrice Sircoulomb,Joshua Paterson,Martin Köbel,Kurosh Rahimi,Paul Hoskins,Dongsheng Tu,Stephanie Lheureux,Amit M. Oza,Laurie Ailles,Laurie Ailles,Diane Provencher,Robert Rottapel,Robert Rottapel,Anne-Marie Mes-Masson +16 more
TL;DR: JAM-A expression is a robust prognostic biomarker of HGSC and may be used to discriminate tumors responsive to therapies targeting EMT and exhibited an enhanced epithelial to mesenchymal transition (EMT) signature.
Journal ArticleDOI
Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
Michael Friedlander,Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung-Gie Kim,Ana Oaknin,Alla Sergeevna Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +18 more
TL;DR: In SOLO1 (NCT01844986), maintenance olaparib resulted in a significant improvement in progression-free survival (PFS) for newly diagnosed, BRCa1- and/or BRCA2-mutated, advanced ovar...
Journal ArticleDOI
Targeting TGFβ Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?
Luisa Bonilla,Amit M. Oza +1 more
TL;DR: Adult granulosa cell tumor (AGCT) is a rare malignancy characterized by FOXL2 (C134W) mutation, an inherent component of the TGFβ pathway, which is a driver of this activity and is a potential target in AGCT.
Journal ArticleDOI
Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Michael Friedlander,Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byung-Tae Kim,Ana Oaknin,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Elizabeth S. Lowe,Robert Hettle,Emuella Flood,P. DiSilvestro +19 more
TL;DR: There were clinically meaningful patient-centred benefits with maintenance olaparib in both QAPFS and TWiST supporting the substantial benefit of PFS improvement seen with olapARib in newly diagnosed advanced OC.